RecruitingNCT07348263

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

International Multicentre Cohort Study on Clinical Manifestations and Response to Therapy in Juvenile Onset Eosinophilic Fasciitis


Sponsor

Meyer Children's Hospital IRCCS

Enrollment

20 participants

Start Date

May 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.


Eligibility

Max Age: 18 Years

Inclusion Criteria5

  • Inclusion criterai:
  • All patients diagnosed from 2000 to 31/12/2026
  • minimum follow-up 6 months
  • Age <18 years at diagnosis;
  • All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable.

Exclusion Criteria3

  • Age ≥18 years at diagnosis;
  • Unwilling to participate into the study;
  • A follow-up period < 6 months.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(15)

University of Alabama at Birmingham

Birmingham, Alabama, United States

SUNY Upstate Pediatric Rheumatology

Syracuse, New York, United States

Children's Hospital Zagreb

Zagreb, Croatia

Hamburger Zentrum für Kinder- und Jugendrheumatologie -

Hamburg, Germany

Ruth Rappaport Children's Hospital of Haifa

Haifa, Israel

Meyer Children's Hospital IRCCS

Florence, FI, Italy

IRCCS Giannina Gaslini,

Genova, Italy

Università di Udine

Udine, Italy

Iuliu Hatieganu University of Medicine and Pharmacy

Cluj-Napoca, Romania

University Children's Hospital

Ljubljana, Slovenia

Hospital Sant Joan de Déu,

Barcelona, Spain

Astrid Lindgren Children's Hospital

Solna, Stockholm County, Sweden

Cerrahpasa Medical School, Istanbul University

Istanbul, Turkey (Türkiye)

Alder Hey Children's Hospital

Liverpool, United Kingdom

Great North Children's Hospital, Newcastle Upon Tyne

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07348263